Evidence map›Paper›PMID 35054869›Full record

ReviewInternational journal of molecular sciences2022

Where Are We with RPE Replacement Therapy? A Translational Review from the Ophthalmologist Perspective.

Raffaele Raimondi, Piero Zollet, Francesco Paolo De Rosa, Panagiotis Tsoutsanis, Matteo Stravalaci, Marianna Paulis, Antonio Inforzato, Mario R Romano

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Microfluidic platform for nanoliter qPCR of several retinal pigment epithelial (RPE) cells.Journal of micromechanics and microengineering : structures, devices, and systems · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Raffaele RaimondiIRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.
Piero ZolletIRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.ORCID 0000-0002-5892-7533
Francesco Paolo De RosaDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.ORCID 0000-0002-1631-1634
Panagiotis TsoutsanisDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.ORCID 0000-0002-0438-422X
Matteo StravalaciIRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.ORCID 0000-0002-5636-4204
Marianna PaulisIRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.
Antonio InforzatoIRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.ORCID 0000-0001-8110-0027
Mario R RomanoDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.
Humanitas University · ITInstitute of Genetic and Biomedical Research · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The retinal pigmented epithelium (RPE) plays a pivotal role in retinal homeostasis. It is therefore an interesting target to fill the unmet medical need of different retinal diseases, including age-related macular degeneration and Stargardt disease. RPE replacement therapy may use different cellular sources: induced pluripotent stem cells or embryonic stem cells. Cells can be transferred as suspension on a patch with different surgical approaches. Results are promising although based on very limited samples. In this review, we summarize the current progress of RPE replacement and provide a comparative assessment of different published approaches which may become standard of care in the future.

Indexed as

OphthalmologistsTranslational Research, BiomedicalClinical Trials as TopicHumansMacular DegenerationRetinal Pigment EpitheliumStargardt Diseaseage related macular degenerationembryonic stem cellsinduced pluripotent stem cellsreplacementretinal pigmented epitheliumStargardt disease

Identifiers

PMID35054869
PMCPMC8775975
OpenAlexW4206182731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.